Gefitinib
Information
- Drug Name
- Gefitinib
- Description
- Entry(CIViC)
- 82
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Expression of EGFRvIII and PTEN was evaluated in 2... | EGFR | EGFR VIII EGFR VIII | Sensitivity | true | CIViC Evidence | detail |
| Expression of EGFRvIII and PTEN was evaluated in 2... | PTEN | PTEN EXPRESSION PTEN EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in KRAS mutant lung and colon ca... | ERBB3 |
ERBB3 OVEREXPRESSION ( ENST00000267101.8 ) ERBB3 OVEREXPRESSION ( ENST00000267101.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| HCC827 cell lines harboring activated PI3K (HCC827... | PIK3CA |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 448 metastatic colorectal cancer pat... | KRAS |
KRAS p.Gly12Cys (p.G12C) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 155 patients with lung adenocarcinomas underwent r... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 155 patients with lung adenocarcinomas underwent r... | MET |
MET AMPLIFICATION ( ENST00000318493.11 ) MET AMPLIFICATION ( ENST00000318493.11 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 155 patients with lung adenocarcinomas underwent r... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Case report of an 81-year old man with lung adenoc... | EGFR |
EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| 5 of 7 colorectal cancer (CRC) cell lines with BRA... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| 90 NSCLC patients with stage IIIB/IV chemotherapy-... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| 90 NSCLC patients with stage IIIB/IV chemotherapy-... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| 48 tumor samples from 41 patients with EGFR mutant... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 48 tumor samples from 41 patients with EGFR mutant... | PIK3CA |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| This small clinical (n=56) study suggests that pat... | EGFR |
EGFR p.Gly719Ser (p.G719S) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Gly719Ser (p.G719S) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| D761Y as a secondary mutation was reported to be a... | EGFR |
EGFR p.Asp761Tyr (p.D761Y) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Asp761Tyr (p.D761Y) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| This open label Phase 3 Trial performed across 36 ... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| The disease control rate of patients with GNAS1 T3... | GNAS |
GNAS p.Leu131= (p.L131=) ( ENST00000306090.12, ENST00000306120.4, ENST00000313949.11, ENST00000349036.9, ENST00000371075.7, ENST00000371098.6, ENST00000371100.9, ENST00000371102.8, ENST00000419558.7, ENST00000423897.7, ENST00000453292.7, ENST00000462499.6, ENST00000467227.6, ENST00000472183.6, ENST00000482112.6, ENST00000491348.5, ENST00000493744.5, ENST00000657090.1, ENST00000663479.2, ENST00000676826.2 ) GNAS p.Leu131= (p.L131=) ( ENST00000306090.12, ENST00000306120.4, ENST00000313949.11, ENST00000349036.9, ENST00000371075.7, ENST00000371098.6, ENST00000371100.9, ENST00000371102.8, ENST00000419558.7, ENST00000423897.7, ENST00000453292.7, ENST00000462499.6, ENST00000467227.6, ENST00000472183.6, ENST00000482112.6, ENST00000491348.5, ENST00000493744.5, ENST00000657090.1, ENST00000663479.2, ENST00000676826.2 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In recurrent lung cancer patients treated with the... | KRAS |
KRAS p.Gly12Ala (p.G12A) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a retrospective study, 166 non-small cell lung ... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a phase 3 clinical trial of East Asian advanced... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| A phase 2 study of 120 stage IIIB-IV lung adenocar... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a study of 6 patients with progressive non-smal... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 14 patients with progressive non-sma... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In recurrent lung cancer patients treated with the... | KRAS |
KRAS p.Gly12Asp (p.G12D) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D) ( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In recurrent lung cancer patients treated with the... | KRAS |
KRAS p.Gly12Cys (p.G12C) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In recurrent lung cancer patients treated with the... | KRAS |
KRAS p.Gly12Val (p.G12V) ( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V) ( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In recurrent lung cancer patients treated with the... | KRAS |
KRAS p.Gly12Ser (p.G12S) ( ENST00000685328.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ser (p.G12S) ( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000556131.2, ENST00000557334.6, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| There is no statistical difference in progression ... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study, 166 non-small cell lung ... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a retrospective study, 166 non-small cell lung ... | KRAS | KRAS MUTATION KRAS MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In non-small cell lung cancer, the appearance of T... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 297 non-small cell lung cancer patie... | EGFR |
EGFR p.Gly719Ala (p.G719A) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Gly719Ala (p.G719A) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| KRAS mutations (N=29 G12, N=1 G13) were the primar... | KRAS |
KRAS p.Gly12Ala (p.G12A) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase 3 clinical trial of East Asian pulmonar... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | N/A | true | CIViC Evidence | detail |
| In a phase 3 clinical trial of Korean, never-smoke... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| Mutational profiling was performed on EGFR exons 1... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a phase 3 clinical trial of non-small cell lung... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Mutational profiling was performed on EGFR exons 1... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study using PC9 cells (EGFR exon 19... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a phase 3 clinical trial of Korean, never-smoke... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Exon 19 deletion has been shown to be correlated w... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| Gefinitib has been shown to be effective in treati... | EGFR |
EGFR p.Gly719Ser (p.G719S) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Gly719Ser (p.G719S) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In NSCLC patients treated with EGFR tyrosine kinas... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Gefinitib has been shown to be effective in treati... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a study of 52 patients with recurrent lung canc... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a phase 3 clinical trial of non-small cell lung... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In 60 patients with NSCLC, Exon 2 KRAS mutations w... | KRAS | KRAS G12/G13 KRAS G12/G13 | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study, a group of 6 participants, 5 with stag... | EGFR | EGFR L861Q EGFR L861Q | Sensitivity | true | CIViC Evidence | detail |
| EGFR L858R was expressed in Ba/F3 cells which do n... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| NSCLC patients with exon 19 deletions in EGFR had ... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| EGFR G719 mutations have been associated with incr... | EGFR | EGFR G719 EGFR G719 | Sensitivity | true | CIViC Evidence | detail |
| Mutational profiling was performed on EGFR exons 1... | EGFR |
EGFR p.Glu746_Ala750del (p.E746_A750del) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Glu746_Ala750del (p.E746_A750del) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Mutational profiling was performed on EGFR exons 1... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Sensitivity | true | CIViC Evidence | detail |
| In a study, 2 participants with stage IV lung aden... | EGFR | EGFR G719D EGFR G719D | Sensitivity | true | CIViC Evidence | detail |
| In a study, 1 participant with stage IV adenocarci... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Sensitivity | true | CIViC Evidence | detail |
| In a study, 1 participant with stage IIIB lung ade... | EGFR |
EGFR p.Lys806Glu (p.K806E) ( ENST00000450046.2, ENST00000275493.7, ENST00000455089.5 ) EGFR p.Lys806Glu (p.K806E) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | false | CIViC Evidence | detail |
| In a study, 1 participant with stage IIIB lung ade... | EGFR | EGFR V834I EGFR V834I | Sensitivity | true | CIViC Evidence | detail |
| In a study, 1 participant with stage IV lung adeno... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Sensitivity | true | CIViC Evidence | detail |
| In a study, 1 participant with stage IV lung adeno... | EGFR | EGFR N842S EGFR N842S | Sensitivity | false | CIViC Evidence | detail |
| In a study, 1 participant with stage IIIB lung ade... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Sensitivity | false | CIViC Evidence | detail |
| EGFR L861 mutations have been associated with incr... | EGFR | EGFR L861Q EGFR L861Q | Sensitivity | true | CIViC Evidence | detail |
| In a study, 1 participant with stage IV lung adeno... | EGFR | EGFR L861Q EGFR L861Q | Sensitivity | true | CIViC Evidence | detail |
| In a cohort of NSCLC patients treated with tyrosin... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a study of 1261 non-small cell lung cancer pati... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a cohort of NSCLC patients tested for mutation ... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | false | CIViC Evidence | detail |
| Double blind Phase II clinical trial found an obje... | EGFR | EGFR EXPRESSION EGFR EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Study found somatic EGFR mutations localized to ex... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Sensitivity | true | CIViC Evidence | detail |
| The result of the analysis found that EGFR gene co... | EGFR |
EGFR COPY NUMBER VARIATION ( ENST00000275493.7 ) EGFR COPY NUMBER VARIATION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| Among TKI-treated patients, increased EGFR gene co... | EGFR |
EGFR COPY NUMBER VARIATION ( ENST00000275493.7 ) EGFR COPY NUMBER VARIATION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a large retrospective study, EGFR exons 18-21 w... | EGFR |
EGFR p.Gly719Ala (p.G719A) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Gly719Ala (p.G719A) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | false | CIViC Evidence | detail |
| In a large retrospective study, EGFR exons 18-21 w... | EGFR | EGFR R705K EGFR R705K | Sensitivity | false | CIViC Evidence | detail |
| In a Japanese Phase III clinical trial, noninferio... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
N/A | false | CIViC Evidence | detail |
| A Japanese Phase III clinical study assessed the n... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
N/A | false | CIViC Evidence | detail |
| A Japanese Phase III clinical study assessed the n... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | N/A | false | CIViC Evidence | detail |
| Lung cancers can accumulate activating mutations i... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this study a gefitinib-sensitive cell-line (HCC... | MET |
MET AMPLIFICATION ( ENST00000318493.11 ) MET AMPLIFICATION ( ENST00000318493.11 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| TOPK (PBK) silencing sensitized lung cancer cells ... | PBK |
PBK OVEREXPRESSION ( ENST00000301905.9 ) PBK OVEREXPRESSION ( ENST00000301905.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Expression of IGF1R in NSCLC cell lines (n=17) was... | IGF1R | IGF1R EXPRESSION IGF1R EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| While EGFR mutation is a strong predictive factor ... | EGFR | EGFR Y1092 PHOSPHORYLATION EGFR Y1092 PHOSPHORYLATION | Sensitivity | true | CIViC Evidence | detail |
| 82 patients treated with gefitinib were retrospect... | EGFR |
EGFR OVEREXPRESSION ( ENST00000275493.7 ) EGFR OVEREXPRESSION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 290 patients with advanced NSCLC, 177 of which ... | EGFR |
EGFR AMPLIFICATION ( ENST00000275493.7 ) EGFR AMPLIFICATION ( ENST00000275493.7 ) |
Sensitivity | false | CIViC Evidence | detail |
| To characterize tumor cell-independent stromal eff... | EGFR | EGFR UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Gefitinib is a small molecule tyrosine kinase inhi... | EGFR | EGFR EXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03866499 | Active, not recruiting | Phase 3 | A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients | April 30, 2021 | February 29, 2024 |
| NCT03849768 | Active, not recruiting | Phase 3 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | February 1, 2019 | June 30, 2023 |
| NCT03333343 | Active, not recruiting | Phase 1 | Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | January 29, 2018 | December 16, 2024 |
| NCT03292133 | Active, not recruiting | Phase 2 | A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | October 31, 2017 | June 30, 2024 |
| NCT03122717 | Active, not recruiting | Phase 1/Phase 2 | Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | May 9, 2017 | April 2026 |
| NCT02856893 | Active, not recruiting | Phase 2 | Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) | October 10, 2017 | December 2027 |
| NCT02411448 | Active, not recruiting | Phase 3 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) | May 6, 2015 | December 16, 2024 |
| NCT03944772 | Active, not recruiting | Phase 2 | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | June 25, 2019 | May 6, 2025 |
| NCT04143607 | Active, not recruiting | Phase 3 | ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC | July 23, 2019 | September 30, 2026 |
| NCT00024154 | Completed | Phase 2 | Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer | February 2002 | |
| NCT00025116 | Completed | Phase 2 | ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | April 24, 2001 | September 22, 2008 |
| NCT00025142 | Completed | Phase 2 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | July 2001 | November 2006 |
| NCT00025207 | Completed | Phase 2 | Gefitinib in Treating Patients With Malignant Mesothelioma | September 2001 | |
| NCT00025350 | Completed | Phase 2 | Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer | October 2001 | June 2006 |
| NCT00025675 | Completed | Phase 2 | Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors | October 9, 2001 | January 2, 2010 |
| NCT00026364 | Completed | Phase 1 | ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer | November 2001 | |
| NCT00027625 | Completed | Phase 1 | Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma | January 28, 2002 | November 1, 2005 |
| NCT00027690 | Completed | Phase 2 | Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer | June 2002 | July 2013 |
| NCT00029003 | Completed | Phase 2 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | December 2001 | |
| NCT00030524 | Completed | Phase 2 | ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer | January 2002 | September 2003 |
| NCT00039390 | Completed | Phase 1 | Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors | April 2002 | |
| NCT00040781 | Completed | Phase 1 | Gefitinib in Treating Children With Refractory Solid Tumors | June 2002 | |
| NCT00040794 | Completed | Phase 2 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | May 2002 | |
| NCT00041106 | Completed | Phase 2 | Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | May 2002 | |
| NCT00042991 | Completed | Phase 1/Phase 2 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | July 2002 | March 2010 |
| NCT00049062 | Completed | Phase 2 | Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer | September 2002 | October 2007 |
| NCT00049543 | Completed | Phase 3 | Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery | September 2002 | April 2011 |
| NCT00049556 | Completed | Phase 2 | Gefitinib in Treating Patients With Cervical Cancer | October 2002 | August 2006 |
| NCT00052208 | Completed | Phase 1/Phase 2 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | March 2002 | |
| NCT00052754 | Completed | Phase 2 | Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma | October 2002 | |
| NCT00057941 | Completed | Phase 2 | Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer | September 2003 | June 2012 |
| NCT00062062 | Completed | Phase 2 | Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer | October 2004 | November 2010 |
| NCT00062270 | Completed | Phase 1/Phase 2 | Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | May 2003 | September 2004 |
| NCT00066339 | Completed | Phase 2 | Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy | May 2003 | |
| NCT00066378 | Completed | Phase 2 | Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer | May 2003 | |
| NCT00068497 | Completed | N/A | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | August 2003 | |
| NCT00071994 | Completed | Phase 2 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | February 2004 | |
| NCT00075439 | Completed | Phase 2 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | December 2003 | |
| NCT00076388 | Completed | Phase 3 | Iressa Versus Docetaxel (Taxotere) | February 2004 | October 2007 |
| NCT00077025 | Completed | Phase 2 | Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer | January 2004 | May 2013 |
| NCT00080743 | Completed | Phase 2 | Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer | January 2004 | November 2005 |
| NCT00083057 | Completed | Phase 1 | Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck | May 2004 | November 2010 |
| NCT00084708 | Completed | Phase 1 | Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors | November 2002 | May 2007 |
| NCT00084786 | Completed | Phase 1 | Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors | March 2004 | |
| NCT00085566 | Completed | Phase 1/Phase 2 | Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer | March 2004 | February 2008 |
| NCT00086957 | Completed | Phase 1/Phase 2 | Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer | January 2004 | August 2015 |
| NCT00095836 | Completed | Phase 2 | Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy | March 2003 | March 2011 |
| NCT00096486 | Completed | Phase 1/Phase 2 | Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer | May 2004 | July 2010 |
| NCT02040064 | Completed | Phase 1 | Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients | January 2014 | March 2016 |
| NCT00012337 | Completed | Phase 2 | ZD 1839 in Treating Patients With Metastatic Kidney Cancer | January 2001 | March 2004 |
| NCT00014144 | Completed | Phase 2 | S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | February 2001 | December 2007 |
| NCT00014170 | Completed | Phase 2 | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | March 2001 | |
| NCT00014183 | Completed | Phase 2 | ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer | January 2001 | August 2005 |
| NCT00016991 | Completed | Phase 2 | ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse | June 2001 | April 2005 |
| NCT00020709 | Completed | Phase 3 | Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | June 2001 | |
| NCT00023699 | Completed | Phase 2 | Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | August 2001 | May 2006 |
| NCT00024089 | Completed | Phase 2 | Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | July 2001 | |
| NCT00239304 | Completed | Phase 1/Phase 2 | Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer | June 2003 | March 2006 |
| NCT00239343 | Completed | Phase 2 | Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer | October 2004 | May 2007 |
| NCT00241475 | Completed | Phase 2 | Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy | December 2003 | October 2005 |
| NCT00242801 | Completed | Phase 3 | Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study | July 2003 | April 2005 |
| NCT00246974 | Completed | Phase 2 | Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT | May 2003 | December 2007 |
| NCT00247481 | Completed | Phase 2 | ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer | September 2002 | June 2005 |
| NCT00252798 | Completed | Phase 1 | ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | July 2002 | October 2005 |
| NCT00255463 | Completed | Phase 2 | Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study | January 2004 | November 2005 |
| NCT00255476 | Completed | Phase 2 | The IRESSA Novel Head and Neck Chemotherapy Evaluation Study | February 2004 | July 2007 |
| NCT00255489 | Completed | Phase 1 | A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer | May 2004 | June 2006 |
| NCT00256711 | Completed | Phase 2 | Phase II Iressa Versus Vinorelbine (INVITE) | July 2004 | February 2006 |
| NCT00259064 | Completed | Phase 2/Phase 3 | Iressa v BSC (Best Supportive Care) in First Line NSCLC | September 2004 | April 2016 |
| NCT00264498 | Completed | Phase 2 | Phase II Iressa & Carbo/Gem in NSCLC | October 2004 | June 2008 |
| NCT00265070 | Completed | Phase 2 | Trial of Iressa in Prostate Cancer Patients | January 2003 | August 2011 |
| NCT00298688 | Completed | Phase 2 | A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer | September 2004 | March 2007 |
| NCT00310154 | Completed | Phase 1 | Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | November 2003 | August 2010 |
| NCT00317772 | Completed | Phase 1/Phase 2 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | September 2, 2004 | November 4, 2020 |
| NCT00319618 | Completed | Phase 2 | Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer | June 2003 | June 2006 |
| NCT00322452 | Completed | Phase 3 | First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia | March 2006 | June 2010 |
| NCT00333294 | Completed | Phase 2 | Phase II Iressa + Irradiation Followed by Chemo in NSCLC | September 2004 | January 2006 |
| NCT00344773 | Completed | Phase 2 | First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation | March 2006 | December 2007 |
| NCT00357734 | Completed | Phase 3 | Iressa Follow-up Trial | January 2005 | May 2015 |
| NCT00372515 | Completed | Phase 1 | High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations | June 2006 | April 2015 |
| NCT00409006 | Completed | Phase 2 | Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers | February 2007 | May 2010 |
| NCT00411047 | Completed | Phase 2 | Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer | September 2005 | December 2012 |
| NCT00455936 | Completed | Phase 3 | First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker | October 2005 | March 2010 |
| NCT00478049 | Completed | Phase 3 | Iressa as Second Line Therapy in Advanced NSCLC-Asia | September 2005 | February 2009 |
| NCT00509002 | Completed | Phase 2 | Iressa Study in Patients With Salivary Gland Cancer | May 2004 | September 2016 |
| NCT00519077 | Completed | Phase 2 | Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck | March 2005 | May 2013 |
| NCT00588445 | Completed | Phase 2 | Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene | June 2004 | September 2010 |
| NCT00608868 | Completed | Phase 4 | SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients | January 2007 | January 2009 |
| NCT00635856 | Completed | Phase 2 | Open Label Trial to Assess Iressa in Prostate Cancer Patients | May 2001 | February 2003 |
| NCT00637026 | Completed | Phase 2 | Ph II Early BC Pre-Surgical Biologic Study | July 2003 | February 2005 |
| NCT00681967 | Completed | Phase 1 | Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer | February 2004 | October 2009 |
| NCT00770588 | Completed | Phase 4 | Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) | September 2008 | February 2011 |
| NCT00807066 | Completed | Phase 3 | Randomized Gefitinib Trial | November 2008 | October 2010 |
| NCT01017874 | Completed | Phase 3 | A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer | November 2009 | October 2014 |
| NCT01024413 | Completed | Phase 3 | Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations | July 2009 | June 2015 |
| NCT01039948 | Completed | Phase 1/Phase 2 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | December 2009 | August 2013 |
| NCT01040780 | Completed | Phase 3 | Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients | February 2009 | December 2011 |
| NCT01203917 | Completed | Phase 4 | Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC | September 2010 | June 2016 |
| NCT01404260 | Completed | Phase 3 | Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer | June 2011 | October 2015 |
| NCT01466660 | Completed | Phase 2 | LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | December 13, 2011 | April 12, 2019 |
| NCT01469000 | Completed | Phase 2 | A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) | February 2012 | November 2017 |
| NCT01485809 | Completed | Phase 2 | Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy | October 2011 | November 2016 |
| NCT01498562 | Completed | Phase 2 | Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer | December 2011 | June 2014 |
| NCT01513174 | Completed | Phase 1/Phase 2 | Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone | August 2011 | July 2016 |
| NCT01544179 | Completed | Phase 3 | A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone | March 15, 2012 | November 20, 2019 |
| NCT01556191 | Completed | Phase 2 | Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR | May 15, 2012 | June 17, 2020 |
| NCT01602289 | Completed | Phase 1 | A Study of LY2875358 in Japanese Participants With Advanced Cancer | June 2012 | August 2014 |
| NCT01610336 | Completed | Phase 2 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | April 5, 2012 | May 27, 2020 |
| NCT01774721 | Completed | Phase 3 | ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | May 9, 2013 | January 27, 2022 |
| NCT01783834 | Completed | Phase 2 | Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients | February 2008 | June 2014 |
| NCT01833572 | Completed | Phase 2 | Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | May 2013 | October 2015 |
| NCT01933347 | Completed | Phase 2 | Third-line Treatment of Gefitinib in NSCLC Patients | April 7, 2014 | April 10, 2018 |
| NCT01982955 | Completed | Phase 1/Phase 2 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | December 23, 2013 | October 14, 2021 |
| NCT02039674 | Completed | Phase 1/Phase 2 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | February 21, 2014 | October 18, 2021 |
| NCT00005806 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | September 1999 | March 2002 |
| NCT02088112 | Completed | Phase 1 | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | March 24, 2014 | March 9, 2021 |
| NCT02148380 | Completed | N/A | Combination of Chemotherapy and Gefitinib as First-line Treatment | May 2014 | December 2015 |
| NCT02179671 | Completed | Phase 2 | Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | July 25, 2014 | June 11, 2016 |
| NCT02374645 | Completed | Phase 1 | A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC | April 2015 | September 14, 2018 |
| NCT02447419 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors | December 3, 2014 | December 1, 2020 |
| NCT02740894 | Completed | Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ? | February 2016 | April 2016 | |
| NCT02804776 | Completed | Phase 2 | PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery | January 27, 2015 | February 21, 2018 |
| NCT02976116 | Completed | Phase 2 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | December 2016 | June 28, 2019 |
| NCT03157310 | Completed | N/A | Bone Metastasis on the Survival of Gefitinib Effective Patients | May 1, 2009 | July 12, 2015 |
| NCT03170180 | Completed | Phase 2 | Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer | March 1, 2017 | December 28, 2021 |
| NCT03653546 | Completed | Phase 2/Phase 3 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | October 29, 2018 | July 12, 2022 |
| NCT00100945 | Completed | Phase 2 | Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer | July 2005 | October 2009 |
| NCT00103051 | Completed | Phase 2 | Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer | December 2004 | |
| NCT00126555 | Completed | Phase 2 | Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer | March 2005 | February 2013 |
| NCT00127829 | Completed | Phase 1 | Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic | July 2005 | January 2008 |
| NCT00130702 | Completed | Phase 2 | Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia | August 2005 | November 2007 |
| NCT00177242 | Completed | Phase 2 | Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma | September 2004 | December 2006 |
| NCT00188617 | Completed | Phase 2 | Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC | January 2005 | November 2009 |
| NCT00193284 | Completed | Phase 2 | Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer | October 2003 | January 2009 |
| NCT00198380 | Completed | Phase 2 | Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature | April 2005 | December 2009 |
| NCT00198393 | Completed | Phase 2 | Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV | November 2004 | December 2008 |
| NCT00206219 | Completed | Phase 3 | Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) | November 2003 | September 2007 |
| NCT00217698 | Completed | Phase 2 | Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | November 2003 | October 2004 |
| NCT00228488 | Completed | Phase 2 | Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma | June 2004 | December 2005 |
| NCT00229697 | Completed | Phase 2 | Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study | October 2003 | June 2015 |
| NCT00234416 | Completed | Phase 1/Phase 2 | IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer | August 2002 | March 2005 |
| NCT00238251 | Completed | Phase 2 | Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases | May 2005 | November 2010 |
| NCT00238797 | Completed | Phase 2 | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme | February 2003 | March 2006 |
| NCT03381430 | Not yet recruiting | N/A | Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR | June 2018 | December 2025 |
| NCT03203590 | Not yet recruiting | Phase 3 | Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients | September 2017 | January 2026 |
| NCT03040973 | Recruiting | Phase 2 | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | July 4, 2017 | July 30, 2027 |
| NCT05834348 | Recruiting | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | June 26, 2023 | February 3, 2025 | |
| NCT00986284 | Suspended | Phase 2 | Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC) | September 2009 | November 2016 |
| NCT00352079 | Terminated | Phase 3 | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | January 4, 2007 | January 6, 2012 |
| NCT02299765 | Terminated | Phase 4 | Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC | December 2014 | October 2017 |
| NCT02326285 | Terminated | Phase 2/Phase 3 | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB | November 2015 | January 2018 |
| NCT01310855 | Terminated | Phase 2 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | May 2011 | January 2014 |
| NCT01405846 | Terminated | Phase 2 | Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib | December 2011 | June 2016 |
| NCT00258297 | Terminated | Phase 2 | Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery | April 2004 | November 2006 |
| NCT00467077 | Terminated | Phase 2 | Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer | September 2004 | March 2011 |
| NCT03599518 | Terminated | Phase 1 | DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | September 21, 2018 | June 29, 2020 |
| NCT00493025 | Terminated | Phase 2 | Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery | April 2005 | March 2013 |
| NCT00088907 | Terminated | Phase 3 | Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer | August 2004 | August 2012 |
| NCT00093652 | Terminated | Phase 1/Phase 2 | Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer | May 2003 | |
| NCT00536107 | Terminated | Phase 4 | Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | October 2007 | August 2009 |
| NCT02588261 | Terminated | Phase 3 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | February 11, 2016 | December 21, 2017 |
| NCT00087334 | Terminated | Phase 1/Phase 2 | Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer | January 2004 | |
| NCT00290719 | Terminated | Phase 1 | Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery | November 2005 | June 2008 |
| NCT00082667 | Terminated | Phase 2 | Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast | October 2002 | June 2005 |
| NCT00091156 | Terminated | Phase 3 | Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | May 2004 | |
| NCT00052585 | Terminated | Phase 2 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer | October 2002 | |
| NCT00033449 | Terminated | Phase 1 | Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer | February 2002 | |
| NCT03766490 | Unknown status | N/A | Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer | March 30, 2019 | December 20, 2020 |
| NCT00319800 | Unknown status | Phase 2 | Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC | February 2006 | March 2007 |
| NCT02282267 | Unknown status | N/A | Blood Detection of EGFR Mutation For Iressa Treatment | October 2014 | February 2018 |
| NCT02319577 | Unknown status | Phase 2 | GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial | March 2012 | December 2015 |
| NCT02338011 | Unknown status | Phase 2/Phase 3 | Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases) | November 2014 | November 2017 |
| NCT00423397 | Unknown status | Phase 1/Phase 2 | Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer | September 2006 | |
| NCT00006049 | Unknown status | Phase 3 | ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | May 2000 | |
| NCT02387086 | Unknown status | Phase 2/Phase 3 | Gefitinib Combined With Thalidomide to Treat NSCLC | May 2015 | May 2017 |
| NCT00497250 | Unknown status | Phase 1 | Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy | July 2007 | October 2009 |
| NCT04028778 | Unknown status | Phase 3 | Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC | April 10, 2019 | December 2022 |
| NCT02484755 | Unknown status | Phase 2 | Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease | June 2015 | |
| NCT02518802 | Unknown status | Phase 3 | Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma | January 2015 | January 2020 |
| NCT00614809 | Unknown status | Phase 2 | Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer | December 2007 | December 2010 |
| NCT02929693 | Unknown status | Phase 3 | Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma | October 2016 | June 2019 |
| NCT01024712 | Unknown status | Phase 2 | Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer | May 2009 | |
| NCT02930954 | Unknown status | Phase 2 | Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance | November 2016 | December 2018 |
| NCT02951637 | Unknown status | Phase 2 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | December 2016 | December 2019 |
| NCT01192243 | Unknown status | Phase 2 | Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients | December 2009 | |
| NCT04358562 | Unknown status | Phase 2 | Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | May 1, 2020 | November 1, 2022 |
| NCT01291823 | Unknown status | Phase 2 | Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer | December 2010 | December 2014 |
| NCT01391260 | Unknown status | Phase 2 | Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC) | July 2011 | July 2017 |
| NCT01405079 | Unknown status | Phase 3 | Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation | September 19, 2011 | December 2020 |
| NCT04425187 | Unknown status | Phase 2 | Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC | June 8, 2020 | December 31, 2022 |
| NCT04575415 | Unknown status | Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study | October 7, 2020 | December 2023 | |
| NCT01502202 | Unknown status | Phase 2 | Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers | March 2012 | February 2015 |
| NCT01510990 | Unknown status | Phase 2 | First Line Gefitinib by FDG-PET Metabolic Response | April 2012 | November 2015 |
| NCT03239015 | Unknown status | Phase 2 | Efficacy and Safety of Precision Therapy in Refractory Tumor | January 1, 2017 | December 31, 2023 |
| NCT03399669 | Unknown status | Phase 2 | The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation | February 17, 2015 | December 31, 2018 |
| NCT01732276 | Unknown status | Phase 2 | The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer | January 2013 | October 2015 |
| NCT01755923 | Unknown status | Phase 2 | Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC | December 2012 | December 2014 |
| NCT03457337 | Unknown status | Phase 2 | S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC | March 28, 2018 | October 31, 2021 |
| NCT03486496 | Unknown status | Phase 2 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation | June 5, 2018 | February 1, 2020 |
| NCT03602027 | Unknown status | N/A | Phase I Study of the Combination of Anlotinib With Gefitinib | August 1, 2018 | February 1, 2019 |
| NCT02031601 | Unknown status | Phase 4 | Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer | January 2014 | December 2017 |
| NCT03656393 | Unknown status | Phase 3 | To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma | August 31, 2018 | September 30, 2020 |
| NCT03758287 | Unknown status | Phase 1/Phase 2 | Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative | November 2016 | July 17, 2023 |
| NCT02824458 | Unknown status | Phase 3 | A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations | June 2016 | December 2023 |
| NCT02836847 | Unknown status | Phase 2 | Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | July 2016 | December 2020 |
| NCT00955695 | Unknown status | Phase 3 | Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer | May 2009 | |
| NCT00616499 | Unknown status | Phase 2 | Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | November 2006 | |
| NCT00006048 | Unknown status | Phase 3 | ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | May 2000 | |
| NCT04239833 | Unknown status | Phase 3 | A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | January 31, 2020 | January 31, 2024 |
| NCT00098462 | Withdrawn | Phase 1/Phase 2 | Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer | October 2004 | |
| NCT00252811 | Withdrawn | Phase 2 | A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer | February 2004 | |
| NCT00268255 | Withdrawn | Phase 1/Phase 2 | Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Iressa
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2003
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2002
- Target (Drug list of Screening Committee of Anticancer Drugs)
- EGFR
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 非小細胞肺がん（EGFR遺伝子変異陽性）